Tripla negatív emlőrák: vizsgálatok itt: Kína

In Kína 134 Also abroad 425

134 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Linhai, Linyi, Nanjing, Nanning, Neijiang, Taiyuan, Ürümqi, Wuhan, Xiamen, Xi'an, Xiangyang, Xuzhou, Zhengzhou
Életkor
18 év and over
People
1000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
3. fázisTaking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Beijing, Changchun, Changsha, Deyang, Guangzhou, Haerbin, Hangzhou, Hefei, Jiangmen, Jinan, Kunming, Linyi, Liuzhou, Nanchang, Nanjing, Nanning, Neijiang, Shanghai, Ürümqi, Wuhan, Xiamen, Xi'an, Xingtai, Zhengzhou
Életkor
18 év and over
People
2400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
3. fázisTaking people
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Where
Shanghai
Életkor
18 év to 70 év
People
424
Run by
Fudan University
See details and how to joinNCT05999149
2. fázisTaking people
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Where
Shanghai
Életkor
18 év to 70 év
People
39
Run by
Fudan University
See details and how to joinNCT06793332
1/2. fázisTaking people
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Where
Beijing, Hubei, Hunan
Életkor
18 év to 75 év
People
42
Run by
Shenzhen Majory Biotechnology Co., Ltd.
See details and how to joinNCT07208149
2. fázisTaking people
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Where
Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Jining, Lanzhou, Mianyang, Nanchang, Nanjing, Qingdao, Shenyang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
Életkor
18 év to 70 év
People
184
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07876557
1/2. fázisTaking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
Életkor
18 év and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
1. fázisTaking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Életkor
18 év and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
2. fázisTaking people
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Where
Jinan
Életkor
18 év to 70 év
People
72
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT06802757
3. fázisTaking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Taiyuan, Wuhan, Xi'an, Yongzhou, Zhengzhou
Életkor
18 év and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
2. fázisTaking people
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Where
Shanghai
Életkor
18 év to 75 év
People
120
Run by
Tianjin ConjuStar Biologics Co., Ltd.
See details and how to joinNCT07080619
2. fázisTaking people
Pucotenlimab and Anlotinib in Combination With Chemotherapy
Where
Hangzhou
Életkor
18 év and over
People
34
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT07896668
2. fázisTaking people
Reverse Triple Negative Immune Resistant Breast Cancer
Where
Shanghai
Életkor
18 év to 70 év
People
90
Run by
Fudan University
See details and how to joinNCT05076682
2. fázisTaking people
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Where
Guangzhou
Életkor
18 év to 70 év
People
430
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06992336
No phaseTaking people
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
Where
Fuzhou, Ningde, Quanzhou, Sanming
Életkor
18 év and over
People
120
Run by
Fujian Cancer Hospital
See details and how to joinNCT07880600
3. fázisTaking people
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Where
Shanghai
Életkor
18 év to 75 év
People
436
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07729956
3. fázisTaking people
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Where
Sichuan
Életkor
18 év to 65 év
People
318
Run by
West China Hospital
See details and how to joinNCT06627712
2. fázisTaking people
Capecitabine in Low Risk Triple Negative Breast Cancer
Where
Shanghai
Életkor
18 év and over
People
198
Run by
Fudan University
See details and how to joinNCT06787339
2. fázisTaking people
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Where
Tianjin
Életkor
18 év to 75 év
People
40
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07372079
3. fázisTaking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xintai, Xuzhou, Zhanjiang, Zhengzhou
Életkor
18 év and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
2. fázisNot yet taking people in Kína
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
Where
Shanghai
Életkor
18 év to 70 év
People
46
Run by
Fudan University
See details and how to joinNCT07419880
2. fázisTaking people
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
Where
Shanghai
Életkor
18 év to 70 év
People
58
Run by
Fudan University
See details and how to joinNCT07638852
3. fázisTaking people
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Where
Beijing
Életkor
18 év to 75 év
People
1000
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07679360
2. fázisTaking people
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Where
Bengbu
Életkor
18 év to 80 év
People
128
Run by
The First Affiliated Hospital of Bengbu Medical University
See details and how to joinNCT05192798
2. fázisTaking people
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Where
Shanghai
Életkor
18 év and over
People
160
Run by
Fudan University
See details and how to joinNCT06649331